Member Info for Snaffleman

Enviro- Please tell us more

He was interviewed at the airport on the Audioboom interview on his way to present the plan to the Zambian authorities

While it is potential profits the market wont price in anything because of their record. Only a banked audited and transparent set of figures will get this to move significantly.

Institutional investors recently invested at 3.5p and after DD they clearly don't agree with you despite the Kabwe licence scenario.

I would rather they take their time and make sure that the detail is fully reviewed and agreed by everyone JLP have a habit of rushing RNSs and mistakes are made and detail missed. As for dates and deadlines they often make a rod for their own back

The display of buy/sell indications on LSE is a perverse waste of time- it looks to me that it is actually deliberately misleading never believe it and look deeper to gauge the current trend. I know they work on spread but I believe many of the long list of sells today are buys as per usual

My main concern is the risk of placings moving forward and at the moment there are a number of unknowns e.g. money required to fund INSPIRE, money required to fund the 80 to 100 sales staff required to market iclaprim (options still being negotiated). One hopes that the market will give significant upside if and when FDA approval happens Q1 2019 but will that upside be negated by dilution- I don�t know and I don�t think anyone does at the moment. Maybe a partnership could be announced and that could change things positively overnight. Many thought the phase 3 results would instigate patner interest from major pharmas but that has not happened . I invested some time ago in the 50s pre phase 3 results and pre American listing and am gob smacked post phase 3 success we are where we are. I sold at a loss and backed SDX where I have clawed back a bit. I like MOTIF and without the dilution risk it is a no brainer but having bought into the story before and been burnt I am reluctant to jump back in at this point. When you look at where IMM got to pre phase 3 results the MOTIF SP is beyond belief.

If what it has got is so good why hast it lost 75% of its value in the last twelve months? Also after it recently rallied from 10p to 17p briefly it retraced very sharply showing no sustainable appetite for the share at the moment. Abramovich has increased his holding which he has not done at AFC (not surprising so he in no mug. Best wishes but not for me but I regularly get it wrong. All the best

That is the problem Smudger I have discovered to my cost over the last 3 years that it has always been a story.

The market is bizzare and surreal. I watched in disbelief as Immupharma multibagged whilst their phase 3 trails whilst the risk of failure (generally about 50%) still existed. Sadly the trial results were disappointing and the SP fell massively yesterday. Motif has had a successful trial is derisked and the SP is drifting down near the pre-phase 3 trial results- unbelievable. Also bank of America increases holding and market still not impressed. I think that MOTIF represents good long term risk reward but some may wish to wait to see if another placing happens. Good value in any event imo

Many don't have any fingers left just black stumps

Why did they not give themselves a risk margin when they published their original targets. It called expectation management and its not rocket science. Sometimes they make a rod for their own back. If they had originally targeted 2000oz per month ironically perception would probably be more positive, The market seems to see one step forward at Hernic and one back at DCM net result SP does not move

reasons: Unnecessary placing for Platcro battered the price down, missed production targets for Hernic, further placing for Instis on already battered down price followed by buying into a company with No mining licence. None of the above was their fault apart from that it was a good year

I would ask how to you expect to take over the world of dump processing when after 3 years you still have not published a plan to produce PCMs at your 1st project.

Colin and Leon were responsible no excuses

Colin has lost the plot. Leon must be embarrassed

Yes please post more

To put the issue to bed as far as my decision to invest was concerned I thought the investment case was good one based only on fast tracked highly profitable PCM production initially at DCM and Hernic as advertised by Colin in 2015. I always assumed for all intents and purposes Tjate has no current value and it would be wonderful and a bonus if and when any value was realised. That is why I never sold when we peaked at 7p last year on licence news I was determined to wait for value to be realised when Hernic was fully up and running. Hence mu dismay at us going backwards by not achieving overambitious targets plus of course no PCMs from DCM This is just my personal take lets just say if and when something happens with Tjate we will be all be very happy investors.

Happy to disagree but Leon specifically said the supply chain was a problem that JLP wanted to help fix. The amount of material is not the issue it is achieving the required throughput

He mentioned previously that supply of raw materials is one main issue why they have not met their production targets and they have no control over the supply chain. Hence very big issue for JLP if we are to achieve targeted production. Failure to do so is one of the reasons we have taken a pasting